在新的《糖尿病诊疗标准》中，ADA于2010年首次正式批准HbA1c作为糖尿病4种诊断方法中的一种，其诊断界值为≥6.5%。对于之前3种诊断标准的建议未变，包括空腹血糖(FPG)为≥126mg/dl，75g口服糖耐量试验2h血糖为≥200mg/dl，或有典型高血糖症状的个体随机血糖为≥200mg/dl。（Diabetes Care January 2010 vol. 33 no. Supplement 1 S4-S10 ）。

原文如下（原文地址）：

Current criteria for the diagnosis of diabetes

• A1C ≥6.5%: The test should be performed in a laboratory using a method that is National Glycohemoglobin Standardization Program (NGSP) certified and standardized to the Diabetes Control and Complications Trial (DCCT) assay.
• FPG ≥126 mg/dl (7.0 mmol/l): Fasting is defined as no caloric intake for at least 8 h.
• 2-h plasma glucose ≥200 mg/dl (11.1 mmol/l) during an oral glucose tolerance test (OGTT): The test should be performed as described by the World Health Organization using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.
• In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis: a random plasma glucose ≥200 mg/dl (11.1 mmol/l).

相关原文链接：

Standards of Medical Care in Diabetes—2010
Executive Summary: Standards of Medical Care in Diabetes—2010

根据《中国医学论坛报》2010年1月7日所载：1、ADA推荐糖化血红蛋白作为更快、更简易的糖尿病诊断标准（诊断切点为6.5%）；2、HbA1c为5.7%-6.4%与空腹血糖受损及糖耐量受损一起，被列为糖尿病风险升高的范畴；3、改善糖尿病治疗的成功策略应包括对HbA1c、血压和血脂控制措施的改进。

本篇日志已有1个评论

1. Firm says:

   2010年03月21日 at 20:12

   希望糖尿病能根治，我家族一直有此类遗传

   回复